Nobel Prize winners face new loss in bid for US CRISPR patents

A U.S. Patent Trial and Appeal Board ruled that the Broad Institute conceived CRISPR use in eukaryotic cells before Jennifer Doudna, Emmanuelle Charpentier and their universities, upholding Broad’s patents in Patent Interference No. 106,115. The University of California said the decision is disappointing but does not affect its more than 60 other U.S. CRISPR patents; Broad said the ruling confirms its patents were properly issued. The decision reinforces Broad’s licensing position for eukaryotic CRISPR applications and could affect licensing negotiations and IP valuations in biotech, but is unlikely to move broad markets immediately.

Analysis

This ruling materially consolidates licensing leverage around holders of eukaryotic-editing claims, raising expected royalty and milestone burdens for preclinical and in-vivo programs over the next 12–36 months. That increases marginal cost of capital for smaller biotech sponsors (higher dilution or partner-seeking) and accelerates M&A incentive for venture-backed plays to secure balance-sheet support before onerous licensing terms crystallize.

Clinical timelines are the critical transmission channel: programs that must demonstrate in-vivo delivery and durable editing now face higher probability of either delayed INDs (due to added legal/contractual steps) or larger upfront partner payments, which will compress near-term free cash flow and push break-even horizons out by 1–3 years for exposed issuers. Conversely, ex-vivo platforms and alternative nuclease approaches (base/prime editors, non-Cas systems) gain relative optionality and become natural consolidation targets for acquirors seeking freedom-to-operate.

Catalyst timeline: expect a sequence of licensing negotiations, defensive cross-licenses, and selective litigation over 6–24 months; an appeals or settlement could flip economics quickly, so positions should be horizon-aware. The true economic impact will be visible in upcoming partner term-sheets and 10-Q/10-K disclosures — watch for changes to royalty rates, milestone structures, and indemnification language as leading indicators of industry-wide ripples.

Contrarian angle: markets often over-index to headline legal winners while underweighting technology workarounds. The proliferation of non‑Broad-encumbered editing modalities suggests the ruling is a speed bump, not a permanent barrier, for the long-term growth of genetic medicines — but it will re-rate near-term optionality away from capital-constrained, in-vivo-dependent firms.

Key Decisions for Investors

• Pair trade (6–12 months): Long ex‑vivo leader (CRSP) / Short in‑vivo‑focused peer (NTLA). Rationale: asymmetric impact on licensing economics; target 2:1 reward-to-risk where downside capped by sector recovery and upside by faster cash generation and M&A takeover premium.
• Options hedge (3–9 months): Buy 3–6 month puts on an in‑vivo‑heavy name (NTLA) sized at 25–40% of equity position and buy 3–6 month calls on an ex‑vivo/alternative‑tech name (EDIT or BEAM) sized similarly. Objective: exploit headline volatility while limiting capital at risk.
• Event monitor (0–6 months): Screen mid-cap biotech filings for revised collaboration terms (higher royalties, larger milestones). Initiate opportunistic longs in names that disclose favorable cross‑licenses or low incremental royalty exposure; target entry when disclosure leads to >10% intraday weakness.
• M&A arb watchlist (12–24 months): Accumulate smaller, non‑in‑vivo‑dependent editing platforms and alternative nuclease plays (base/prime editors) on weakness — these are high-probability acquisition targets for large pharmas seeking freedom‑to‑operate. Position size 1–3% NAV each, take profits on approach of announced deals.